Momenta Pharmaceuticals, Inc. (MNTA)

[jbog]

Sales in the US were USD 820 million (-15% cc), mainly due to pricing pressure in retail generics. US Biopharma sales increased 2% (cc), as the continued double-digit growth of Zarxio was partly offset by the slowdown of Omnitrope and Glatopa 20mg.


I don't believe they are referring to a slowdown of Glatopa sales to Teva's product but more of Copaxones decrease in the MS world.